Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)

BCR gene fused ABL kinase is the critical driving force for the Philadelphia Chromosome positive (Ph+) Chronic Myeloid Leukemia (CML) and has been extensively explored as a drug target. With a structure-based drug design approach we have discovered a novel inhibitor CHMFL-074, that potently inhibits...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Liu, Feiyang, Wang, Beilei, Wang, Qiang, Qi, Ziping, Chen, Cheng, Kong, Lu-Lu, Chen, Ji-Yun, Liu, Xiaochuan, Wang, Aoli, Hu, Chen, Wang, Wenchao, Wang, Huiping, Wu, Fan, Ruan, Yanjie, Qi, Shuang, Liu, Juan, Zou, Fengming, Hu, Zhenquan, Wang, Wei, Wang, Li, Zhang, Shanchun, Yun, Cai-Hong, Zhai, Zhimin, Liu, Jing, Liu, Qingsong
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2016
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5216742/
https://ncbi.nlm.nih.gov/pubmed/27322145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10037
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg